Syros Pharmaceuticals Valuation
| SYRS Stock | USD 0.26 0.01 3.70% |
Syros Pharmaceuticals seems to be undervalued based on Macroaxis valuation methodology. Our model measures the value of Syros Pharmaceuticals from inspecting the company fundamentals such as Current Valuation of 8.85 M, return on equity of -7.77, and Shares Owned By Insiders of 0.87 % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Syros Pharmaceuticals' valuation include:
Price Book 10.6509 | Enterprise Value 8.8 M | Enterprise Value Ebitda (0.41) | Price Sales 17.8651 | Enterprise Value Revenue 22.4121 |
Undervalued
Today
Please note that Syros Pharmaceuticals' price fluctuation is dangerous at this time. Calculation of the real value of Syros Pharmaceuticals is based on 3 months time horizon. Increasing Syros Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Syros stock is determined by what a typical buyer is willing to pay for full or partial control of Syros Pharmaceuticals. Since Syros Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Syros Stock. However, Syros Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.26 | Real 5.5 | Target 21.25 | Hype 0.23 |
The intrinsic value of Syros Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Syros Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Syros Pharmaceuticals helps investors to forecast how Syros stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Syros Pharmaceuticals more accurately as focusing exclusively on Syros Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Syros Pharmaceuticals' intrinsic value based on its ongoing forecasts of Syros Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Syros Pharmaceuticals' closest peers.
Syros Pharmaceuticals Cash |
|
Syros Valuation Trend
Syros Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of Syros Pharmaceuticals' financial worth over time. Using both Syros Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Syros Pharmaceuticals Total Value Analysis
Syros Pharmaceuticals is at this time projected to have valuation of 8.85 M with market capitalization of 6.9 M, debt of 62.08 M, and cash on hands of 244.48 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Syros Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.85 M | 6.9 M | 62.08 M | 244.48 M |
Syros Pharmaceuticals Investor Information
About 76.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.07. Syros Pharmaceuticals had not issued any dividends in recent years. The entity had 1:10 split on the 19th of September 2022. Based on the key indicators related to Syros Pharmaceuticals' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Syros Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Syros Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Syros Pharmaceuticals has an asset utilization ratio of 5.91 percent. This implies that the Company is making $0.0591 for each dollar of assets. An increasing asset utilization means that Syros Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Syros Pharmaceuticals Ownership Allocation
Syros Pharmaceuticals shows a total of 26.83 Million outstanding shares. The majority of Syros Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Syros Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Syros Pharmaceuticals. Please pay attention to any change in the institutional holdings of Syros Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Syros Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 9.94 M. Net Loss for the year was (164.57 M) with profit before overhead, payroll, taxes, and interest of 14.88 M.About Syros Pharmaceuticals Valuation
The stock valuation mechanism determines Syros Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Syros Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Syros Pharmaceuticals. We calculate exposure to Syros Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Syros Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 7.7 M | 7 M | |
| Pretax Profit Margin | (16.56) | (17.39) | |
| Operating Profit Margin | (12.98) | (13.63) | |
| Net Loss | (16.56) | (17.39) | |
| Gross Profit Margin | 0.77 | 0.81 |
Syros Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Syros Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 28.3 M |
Syros Pharmaceuticals Current Valuation Indicators
Syros Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Syros Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Syros Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Syros Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Syros Pharmaceuticals' worth.Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.